Moderna Vaccine 96 Per Cent Effective In 12-17 Year-Olds, Study Shows

Two-thirds of the 3,235 participants in trials in the United States received the vaccine and one-third were given a placebo.

Moderna said Thursday its Covid-19 vaccine is 96 percent effective among youths aged 12 to 17, according to the results of its first clinical trials.  Two-thirds of the 3,235 participants in trials in the United States received the vaccine and one-third were given a placebo.  The study "showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date," the company said. Tests detected 12 cases of coronavirus 14 days after the first shot. For these intermediate results, participants were followed up on average 35 days after the second injection.